NSE · JUBLPHARMA
Jubilant Pharmova Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹67 Cr with net profit ₹7 Cr — a 10.88% net margin, versus 4.77% the period before.
Shareholding
As of 2026-06-30
- Promoter47.68%
- Public24.05%
- FII15.87%
- DII12.4%
82,703 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.51× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #4 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,47,470 Cr | 83.06 | 14.77 | 15.32% | 26.05% |
| Neuland Laboratories Ltd. | ₹30,195 Cr | 60.66 | 16.12 | 19.42% | 20.99% |
| Acutaas Chemicals Limited | ₹27,703 Cr | 71.73 | 16.72 | 21.54% | 26.42% |
| Jubilant Pharmova Ltd.(this company) | ₹16,330 Cr | 42.09 | 2.3 | 5.62% | 4.11% |
| SMS Pharmaceuticals Ltd. | ₹4,340 Cr | 42.4 | 5.52 | 12.98% | 11.41% |
| Aarti Drugs Ltd. | ₹3,911 Cr | 20.3 | 2.52 | 12.58% | 7.14% |
| Hikal Limited | ₹2,774 Cr | 65.39 | 2.31 | 3.03% | -1.96% |
| Beta Drugs Limited | ₹2,349 Cr | 51.52 | 9.56 | 16.95% | 11.11% |
| NGL Fine Chem Limited | ₹1,642 Cr | 28.71 | 4.99 | 14.62% | 10.67% |
| Fermenta Biotech Ltd. | ₹1,397 Cr | 25.52 | 3.44 | 17.67% | 11.68% |
AI analysis
AI-generated · google/gemini-2.5-flashJubilant Pharmova Ltd. is listed with a market capitalization of Rs 16284 Cr. The company's revenue stands at Rs 7291.3 Cr, and it reported an EPS of 52.93. The Price-to-Earnings ratio is 16.8, and the Book Value per share is Rs 395.88.
Positives
- +The number of shareholders has increased from 32651 in September 2016 to 82703 in June 2026.
Negatives
- −Promoter share pledge has increased from 3.51% in June 2018 to 6.58% as of June 2026.
- −Promoter holding has decreased from an undisclosed figure to 47.67% from previous periods where only pledge data was available.
- −Quarterly net profit decreased from Rs 153.6 Cr in March 2025 to Rs 55.9 Cr in December 2025.
- −Return on Capital Employed (ROCE) is 6.41%, which is lower than the Return on Equity (ROE) of 9.5%.
Financial Performance
Jubilant Pharmova Ltd. reported a revenue of Rs 7291.3 Cr. The company's net profit for March 2026 was Rs 119.4 Cr, based on quarterly results. In previous quarters, net profit fluctuated, recording Rs 55.9 Cr in December 2025 and Rs 120.3 Cr in September 2025.
Profitability & Returns
The company's Return on Equity (ROE) is 9.5% and Return on Capital Employed (ROCE) is 6.41%. The Earnings Per Share (EPS) is Rs 52.93. Over the last four quarters, net profit has ranged from Rs 55.9 Cr to Rs 153.6 Cr.
Balance Sheet Summary
Jubilant Pharmova Ltd. has a debt-to-equity ratio of 0.55. The book value per share is Rs 395.88. The company's quarterly EBIDTA has fluctuated, from a high of Rs 262.1 Cr in March 2025 to a low of Rs 189.3 Cr in December 2025.
Ownership & Pledges
Promoter holding in Jubilant Pharmova Ltd. is 47.67%, with 6.58% of promoter shares pledged. Public shareholding stands at 24.05%. The total number of shareholders is 82703 as of June 2026.
Data as of — price: 2026-09-12 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.